Linagliptin was added to metformin and/or Insulin, in subjects with type 2 diabetes and Stage I–III chronic kidney disease but without any established adverse cardiovascular event (such as history of myocardial infarction or cerebral stroke). This evidence concerns the gene INS and chronic kidney disease.